Alliance Pharma confirmed plans to open a bioanalytical laboratory in Brisbane, Australia to multiply the bioanalytical support in the region.
“With the speed to start Phase I studies, quality of clinical sites and a favorable Australian R&D tax credit, Australia is an optimal market for early phase clinical research,” said Alliance CCO Vito Saccente. “Alliance will not only be able to provide services critical to this market, but also when these compounds move to Phase II, we are well-positioned to transfer methods without losing critical knowledge and can continue to support the progression of clinical development for our clients.”
The new establishment named Alliance Pharma Pty, Ltd., spanning 20,000-square-foot, will begin its preclinical and clinical testing operations this November 2022.
Under the terms of the agreement, Alliance will have the ability to transfer and continue bioanalytical methods on a global scale, particularly across sites in the U.S. and Europe.
The launch follows the company’s recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC.
The new lab will carry out related LC-MS, ligand binding, flow cytometry, ELISpot and PCR instrumentation methods. Alliance Pharma Pty, Ltd. President Hao (Jason) Wang, Ph.D.) will oversee the new facility’s team of scientists.